Aix-en-Provence

Affluent Medical : H1 2023 results. Major advances in clinical programs. Extension of cash horizon to February 2024.

Retrieved on: 
Thursday, September 28, 2023
Artus, NYHA, US Foods, Urinary incontinence, Disease, Human, Statutory auditor, Tricuspid valve, Myocardial infarction, DSMB, Butterfly valve, Hospital, Boston Scientific, Bank statement, Abbott, Anatomy, Aortic stenosis, Food, Clinical trial, Optimization, Quality of life, Minerva, MR, Kalio, Doctor of Philosophy, TAVI, New York Heart Association Functional Classification, Medtronic, Mitral regurgitation, MD, Patient, Mitral valve, Risk, Data, CEST, Engineering, Regulatory News Service, ISIN, DSM-IV codes, Neurostimulation, FDA, Death, Aix-en-Provence, III, Medtech, Pharmaceutical industry, Medical imaging, Medical device, Nursing, Fine chemical, Science

Since early 2023, Affluent Medical has been developing its medical devices and announced important clinical advances in each of its three programs.

Key Points: 
  • Since early 2023, Affluent Medical has been developing its medical devices and announced important clinical advances in each of its three programs.
  • This transcatheter approach avoids an invasive "open heart" procedure and associated complications to treat mitral valve insufficiency.
  • Affluent Medical believes that Kalios would avoid further intervention for potentially 30-40% of patients over a five-year horizon.
  • This transaction would be intended to finance ongoing clinical programs and could receive the support of its reference shareholders.

EQS-News: Affluent Medical SA: H1 2023 RESULTS - Major advances in clinical programs - Extension of cash horizon to February 2024

Retrieved on: 
Thursday, September 28, 2023
Artus, NYHA, US Foods, Urinary incontinence, Disease, Human, Statutory auditor, Tricuspid valve, Myocardial infarction, DSMB, Butterfly valve, Hospital, Boston Scientific, Bank statement, Abbott, Anatomy, Aortic stenosis, Food, Clinical trial, Optimization, Quality of life, Minerva, MR, Kalio, Doctor of Philosophy, TAVI, New York Heart Association Functional Classification, Medtronic, Mitral regurgitation, MD, Patient, Mitral valve, Risk, Data, CEST, Engineering, ISIN, DSM-IV codes, Neurostimulation, FDA, Death, Aix-en-Provence, III, Medtech, Medical imaging, Medical device, Pharmaceutical industry, Nursing, Fine chemical, Science

Since early 2023, Affluent Medical has been developing its medical devices and announced important clinical advances in each of its three programs.

Key Points: 
  • Since early 2023, Affluent Medical has been developing its medical devices and announced important clinical advances in each of its three programs.
  • In March 2023, Affluent Medical announced the successful first implantation of the Epygon biomimetic mitral heart valve in a patient with a severe mitral valve insufficiency profile combined with several comorbidity factors.
  • Affluent Medical believes that Kalios would avoid further intervention for potentially 30-40% of patients over a five-year horizon.
  • This transaction would be intended to finance ongoing clinical programs and could receive the support of its reference shareholders.

Affluent Medical announces positive clinical results and further insights to enhance its strategy on Structural Heart activities.

Retrieved on: 
Saturday, September 16, 2023
NYHA, CE, US Foods, Myocardial infarction, DSMB, Boston Scientific, Anatomy, Perception, Clinical trial, Optimization, IC, ICS, MR, Trial of the century, MDR, Medtronic, Mitral regurgitation, LVOT, Patient, Mitral valve, Regulatory News Service, ISIN, Tricuspid valve, FDA, Aix-en-Provence, Medtech, Food, Safety, Pharmaceutical industry, Medical device, Medical imaging, Hospital, EU

Affluent Medical announces positive clinical results and further insights to enhance its strategy on Structural Heart activities.

Key Points: 
  • Affluent Medical announces positive clinical results and further insights to enhance its strategy on Structural Heart activities.
  • The results reported today consists of an interim data package of the first 20 patients treated at five centers across Europe at 1 year after implantation.
  • The clinical pilot study ‘Minerva’ evaluating the minimally invasive Epygon medical device to treat mitral valve regurgitation is currently being conducted in several clinical trial centers.
  • As the clinical study is progressing, Affluent Medical recently advanced 2 new valve sizes (40 & 42 size).

EQS-News: Affluent Medical announces positive clinical results and further insights to enhance its strategy on Structural Heart activities

Retrieved on: 
Saturday, September 16, 2023
NYHA, CE, US Foods, Myocardial infarction, DSMB, Boston Scientific, Anatomy, Perception, Clinical trial, Optimization, IC, ICS, MR, Trial of the century, MDR, Medtronic, Mitral regurgitation, LVOT, Patient, Mitral valve, ISIN, Tricuspid valve, FDA, Aix-en-Provence, Medtech, Food, Safety, Medical device, Pharmaceutical industry, Medical imaging, Hospital, EU

The results reported today consists of an interim data package of the first 20 patients treated at five centers across Europe at 1 year after implantation.

Key Points: 
  • The results reported today consists of an interim data package of the first 20 patients treated at five centers across Europe at 1 year after implantation.
  • From the 4 patients adjusted peri operatively excellent results were observed (residual mitral regurgitation (MR) grade
  • The clinical pilot study ‘Minerva’ evaluating the minimally invasive Epygon medical device to treat mitral valve regurgitation is currently being conducted in several clinical trial centers.
  • As the clinical study is progressing, Affluent Medical recently advanced 2 new valve sizes (40 & 42 size).

EQS-News: Affluent Medical strengthens management team to advance its development

Retrieved on: 
Monday, July 17, 2023
Edwards, Christophe, IPO, CET, Fresenius (company), Pathology, Merck Group, Vregille, Doctor of Philosophy, CDO, Euronext Paris, Medtronic, Patient, CFO, Knowledge, Growth, Wealth, Johnson & Johnson, Regulatory affairs, VTC, Aix-en-Provence, Medtech, Covidien, BD, Urinary incontinence, Pharmaceutical industry, Management

Sébastien Ladet, CEO of Affluent Medical, commented: "I am delighted to welcome Christophe de Vregille and Benjamin Renault to the Affluent Medical management team at a time when we are approaching several decisive stages in the deployment of our development strategy.

Key Points: 
  • Sébastien Ladet, CEO of Affluent Medical, commented: "I am delighted to welcome Christophe de Vregille and Benjamin Renault to the Affluent Medical management team at a time when we are approaching several decisive stages in the deployment of our development strategy.
  • Benjamin brings a wealth of experience and knowledge in medical device development, which will be instrumental in preparing for commercialization and our expansion on international markets."
  • Benjamin Renault has over 15 years' experience in the development and international deployment of medical devices.
  • Overview of Affluent Medical’s management and leadership team:
    Christophe Giot, M.D., Chief Medical Officer and Vice President Clinical Affairs (Edwards, Terumo, Sanofi)
    Céline Buard, Marketing Director (Johnson & Johnson, BD, Eyetech Care)
    Eric Jague, Director of Regulatory Affairs (Medtronic, Fresenius Kabi)

Affluent Medical strengthens management team to advance its development.

Retrieved on: 
Monday, July 17, 2023
Edwards, Christophe, IPO, CET, Fresenius (company), Pathology, Merck Group, Vregille, Doctor of Philosophy, CDO, Euronext Paris, Medtronic, Patient, Regulatory News Service, CFO, Knowledge, Growth, Wealth, Johnson & Johnson, Regulatory affairs, VTC, Aix-en-Provence, Medtech, Covidien, BD, Urinary incontinence, Risk management, Pharmaceutical industry, Management

Affluent Medical strengthens management team to advance its development.

Key Points: 
  • Affluent Medical strengthens management team to advance its development.
  • Sébastien Ladet, CEO of Affluent Medical comments: "I am delighted to welcome Christophe de Vregille and Benjamin Renault to the Affluent Medical management team at a time when we are approaching several decisive stages in the deployment of our development strategy.
  • Benjamin Renault has over 15 years' experience in the development and international deployment of medical devices.
  • Overview of Affluent Medical’s management and leadership team:
    Christophe Giot, M.D., Chief Medical Officer and Vice President Clinical Affairs (Edwards, Terumo, Sanofi)
    Céline Buard, Marketing Director (Johnson & Johnson, BD, Eyetech Care)
    Eric Jague, Director of Regulatory Affairs (Medtronic, Fresenius Kabi)

Affluent Medical : Increase in resources allocated to the liquidity contract with Kepler Cheuvreux.

Retrieved on: 
Monday, July 10, 2023
Kepler, Regulatory News Service, ISIN, AMF, Pathology, Aix-en-Provence, Medtech, Urinary incontinence, Kepler Cheuvreux, Medical device

Affluent Medical : Increase in resources allocated to the liquidity contract with Kepler Cheuvreux.

Key Points: 
  • Affluent Medical : Increase in resources allocated to the liquidity contract with Kepler Cheuvreux.
  • Aix-en-Provence, July 10, 2023 - 5:30 pm CET- Affluent Medical (ISIN code: FR0013333077 – ticker: AFME), a French MedTech specializing in the international development and industrialization of innovative medical prostheses, at a clinical stage, to treat mitral heart valve pathology and urinary incontinence, today announced an increase in the resources allocated to the liquidity contract entered into with Kepler Cheuvreux, with the aim of improving the liquidity of the share.
  • 2021-01 of June 22, 2021 (the "AMF Decision"), Affluent Medical today increased the resources allocated to the liquidity contract with Kepler Cheuvreux by 35,000 euros.
  • Following this increase in the cash amount allocated to the liquidity contract, the available resources are as follows:

EQS-News: Affluent Medical Presents Poster on First Successful Procedure with Epygon at the 2023 CSI Conference in Frankfurt

Retrieved on: 
Wednesday, June 28, 2023
Moyamoya disease, Heart, NYHA, Suture, Tricuspid valve, CSI, Diabetes, Cardiac rehabilitation, EACTS, Echocardiography, LVEF, Health status of Asian Americans, Minerva, Valve, Infarction, Euronext Paris, Mitral regurgitation, Patient, Mitral valve, Risk, CEST, Annual general meeting, European Association for Cardio-Thoracic Surgery, Aix-en-Provence, III, Medtech, New York Heart Association Functional Classification, Safety, Urinary incontinence, Medical device

Abstract Title: TRANSCATHETER MITRAL VALVE IMPLATATION WITH THE EPYGON PROSTHESIS: FIRST-IN-HUMAN

Key Points: 
  • Abstract Title: TRANSCATHETER MITRAL VALVE IMPLATATION WITH THE EPYGON PROSTHESIS: FIRST-IN-HUMAN
    “We are excited to inform the specialist audience about the first successful procedure with our Epygon system,” said Dr. Christophe Giot, Vice President Clinical Affairs.
  • “Our device is the only biomimetic transcatheter cardiac mitral valve in development that mimics the native mitral valve and physiological blood flow.
  • The objective of the study is to evaluate the safety and efficacy of Epygon valve implantation at 30 days.
  • Affluent Medical anticipates presenting interim results from the first five patients of the Minerva pilot study at the Annual Meeting of the European Association for Cardio-Thoracic Surgery (EACTS) in October 2023.

National Press Club Leadership Signs Open Letter On Chinese Journalist Yuyu Dong

Retrieved on: 
Wednesday, May 31, 2023
Walter Hines Page School of International Relations, Journalism, Guangming Daily, Crime, Life, Neman, Harvard University, Diplomacy, Politico, Editorial, National Press Club (United States), The New York Times Magazine, Le Journal, The New Yorker, Press club, University of Tokyo, Aix-en-Provence, El Diario La Prensa, The Chosun Ilbo, Multimedia, Ages, Revolution, History, Newsroom, Sant'Anna School of Advanced Studies, Government, New Yorker, Lüshi Chunqiu, Harper, Bloomberg News, Book, WeChat, Fairbank Center for Chinese Studies, The New York Times, Risk, University, Lunch, School, Ethics, Institute for Advanced Study, Defense News, Letter, Diplomatic correspondence, Fashion design, Sinology

WASHINGTON, May 31, 2023 /PRNewswire/ -- Following is a statement from Eileen O'Reilly, president of the National Press Club, and Gil Klein, president of the National Press Club Journalism Institute, on an open letter signed by leading journalists in support of Chinese journalist Yuyu Dong.

Key Points: 
  • WASHINGTON, May 31, 2023 /PRNewswire/ -- Following is a statement from Eileen O'Reilly, president of the National Press Club, and Gil Klein, president of the National Press Club Journalism Institute, on an open letter signed by leading journalists in support of Chinese journalist Yuyu Dong.
  • Mr. Dong is well known to western media and scholars, and this is also not a crime under Chinese law.
  • We encourage other journalists to also sign the attached letter which was drafted by some of Mr. Dong's Nieman colleagues."
  • On Feb. 21, 2022 Mr. Dong was detained by Chinese law enforcement officials while having lunch with an officer from the Japanese embassy.

Affluent Medical : Availability of the Universal Registration Document Universal Registration Document (URD) 2022

Retrieved on: 
Wednesday, April 26, 2023
Bank statement, Pathology, XBRL, Share repurchase, URD, ESEF, Regulatory News Service, ISIN, AMF, Mortality, Aix-en-Provence, Medtech, Urinary incontinence, Medical device, Pharmaceutical industry

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • An English version of the 2022 Universal Registration Document will be made available shortly.
  • Affluent Medical develops next-generation, mini-invasive, innovative, adjustable, and biomimetic implants to restore critical physiological functions.
  • KaliosTM, the first mitral adjustable annuloplasty ring, should be the first Affluent Medical device to be marketed.